American Journal of Kidney Diseases
Volume 52, Issue 5 , Pages 811-825 , November 2008

KDOQI US Commentary on the KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in CKD

  • Craig E. Gordon, MD, MS

      Affiliations

    • Tufts Center for Guideline Development and Implementation, Tufts Medical Center, Boston, MA
    • ,
  • Ethan M. Balk, MD, MPH

      Affiliations

    • Tufts Center for Guideline Development and Implementation, Tufts Medical Center, Boston, MA
    • ,
  • Bryan N. Becker, MD

      Affiliations

    • University of Wisconsin School of Medicine and Public Health, Madison, WI
    • ,
  • Peter A. Crooks, MD

      Affiliations

    • Kaiser Permanente–Southern California, Los Angeles, CA
    • ,
  • Bertrand L. Jaber, MD, MS

      Affiliations

    • Caritas St Elizabeth's Medical Center, Tufts University School of Medicine, Boston, MA
    • ,
  • Cynda A. Johnson, MD, MBA

      Affiliations

    • Virginia Tech Carilion School of Medicine, Roanoke, VA
    • ,
  • Maureen A. Michael, BSN, MBA

      Affiliations

    • Central Florida Kidney Centers Inc, Orlando, FL
    • ,
  • Brian J.G. Pereira, MD

      Affiliations

    • AMAG Pharmaceuticals Inc, Cambridge, MA
    • ,
  • Katrin Uhlig, MD, MS

      Affiliations

    • Tufts Center for Guideline Development and Implementation, Tufts Medical Center, Boston, MA
    • ,
  • Adeera Levin, MD

      Affiliations

    • St Paul's Hospital, Vancouver, Canada

References 

  1. Eknoyan G, Lameire N, Barsoum R, et al. The burden of kidney disease: Improving global outcomes. Kidney Int. 2004;66:1310–1314
  2. Kidney Disease: Improving Global Outcomes (KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease). Kidney Int Suppl. 2008;109:S1–S99
  3. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–714
  4. Dalrymple LS, Koepsell T, Sampson J, et al. Hepatitis C virus infection and the prevalence of renal insufficiency. Clin J Am Soc Nephrol. 2007;2:715–721
  5. Tsui JI, Vittinghoff E, Shlipak MG, O'Hare AM. Relationship between hepatitis C and chronic kidney disease: Results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol. 2006;17:1168–1174
  6. Tsui JI, Vittinghoff E, Shlipak MG, et al. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med. 2007;167:1271–1276
  7. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Meta-analysis: Effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther. 2004;20:1271–1277
  8. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Hepatitis C virus antibody status and survival after renal transplantation: Meta-analysis of observational studies. Am J Transplant. 2005;5:1452–1461
  9. Uhlig K, Macleod A, Craig J, et al. Grading evidence and recommendations for clinical practice guidelines in nephrology (A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)). Kidney Int. 2006;70:2058–2065
  10. Fervers B, Burgers JS, Haugh MC, et al. Adaptation of clinical guidelines: Literature review and proposition for a framework and procedure. Int J Qual Health Care. 2006;18:167–176
  11. Schunemann HJ, Fretheim A, Oxman AD. Improving the use of research evidence in guideline development: 13 (Applicability, transferability and adaptation. Health research policy and systems). Health Res Policy Syst. 2006;4:25
  12. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147–1171
  13. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology. 2006;130:231–264quiz, 214-237
  14. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 (June 10-12, 2002). Gastroenterology. 2002;123:2082–2099
  15. Tokars JI, Arduino MJ, Alter MJ. Infection control in hemodialysis units. Infect Dis Clin North Am. 2001;15:797–812viii
  16. Alter MJ, Kuhnert WL, Finelli L Centers for Disease Control and Prevention. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. MMWR Recomm Rep. 2003;52:1–1315; quiz, CE11-CE14
  17. Soma J, Saito T, Taguma Y, et al. High prevalence and adverse effect of hepatitis C virus infection in type II diabetic-related nephropathy. J Am Soc Nephrol. 2000;11:690–699
  18. Stehman-Breen C, Willson R, Alpers CE, Gretch D, Johnson RJ. Hepatitis C virus-associated glomerulonephritis. Curr Opin Nephrol Hypertens. 1995;4:287–294
  19. Fissell RB, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: The DOPPS. Kidney Int. 2004;65:2335–2342
  20. dos Santos JP, Loureiro A, Cendoroglo Neto M, Pereira BJ. Impact of dialysis room and reuse strategies on the incidence of hepatitis C virus infection in haemodialysis units. Nephrol Dial Transplant. 1996;11:2017–2022
  21. Bruno S, Battezzati PM, Bellati G, et al. Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C. J Hepatol. 2001;34:748–755
  22. Yoshida H, Arakawa Y, Sata M, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology. 2002;123:483–491
  23. Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med. 1997;127:875–881
  24. Reichard O, Glaumann H, Fryden A, Norkrans G, Wejstal R, Weiland O. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J Hepatol. 1999;30:783–787
  25. Yoshida H, Shiratori Y, Moriyama M, et al. IHIT Study Group Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan (Inhibition of Hepatocarcinogenesis by Interferon Therapy). Ann Intern Med. 1999;131:174–181
  26. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982
  27. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet. 2001;358:958–965
  28. Hoffmann-La Roche Inc. Peginterferon alfa-2a [package insert]. Nutley, NJ: Hoffmann-La Roche Inc; 2002;
  29. Schering Corp. Peginterferon alfa-2b [package insert]. Kenilworth, NJ: Schering Corp; 2001;
  30. Schering Corp. Ribavirin [package insert]. Kenilworth, NJ: Schering Corp; 2003;
  31. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Meta-analysis: Interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther. 2003;18:1071–1081
  32. Russo MW, Goldsweig CD, Jacobson IM, Brown RS. Interferon monotherapy for dialysis patients with chronic hepatitis C: An analysis of the literature on efficacy and safety. Am J Gastroenterol. 2003;98:1610–1615
  33. Kokoglu OF, Ucmak H, Hosoglu S, et al. Efficacy and tolerability of pegylated interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J Gastroenterol Hepatol. 2006;21:575–580
  34. Russo MW, Ghalib R, Sigal S, Joshi V. Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant. 2006;21:437–443
  35. Sporea I, Popescu A, Sirli R, et al. Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis. World J Gastroenterol. 2006;12:4191–4194
  36. Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation. 1995;59:1426–1431
  37. Rostaing L, Modesto A, Baron E, Cisterne JM, Chabannier MH, Durand D. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron. 1996;74:512–516
  38. Kamar N, Sandres-Saune K, Selves J, et al. Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: Effects on renal function and liver histology. Am J Kidney Dis. 2003;42:184–192
  39. Mandal AK, Kraus ES, Samaniego M, et al. Shorter waiting times for hepatitis C virus seropositive recipients of cadaveric renal allografts from hepatitis C virus seropositive donors. Clin Transpl. 2000;14:391–396
  40. Castell J, Gutierrez G. [Outbreak of 18 cases of hepatitis C in a hemodialysis unit]. Gaceta Sanitaria/SESPA. 2005;19:214–220
  41. Kondili LA, Genovese D, Argentini C, et al. Nosocomial transmission in simultaneous outbreaks of hepatitis C and B virus infections in a hemodialysis center. Eur J Clin Microbiol Infect Dis. 2006;25:527–531
  42. Savey A, Simon F, Izopet J, Lepoutre A, Fabry J, Desenclos JC. A large nosocomial outbreak of hepatitis C virus infections at a hemodialysis center. Infect Control Hosp Epidemiol. 2005;26:752–760
  43. Le Pogam S, Le Chapois D, Christen R, Dubois F, Barin F, Goudeau A. Hepatitis C in a hemodialysis unit: Molecular evidence for nosocomial transmission. J Clin Microbiol. 1998;36:3040–3043
  44. Thompson NBS: Hepatitis C Virus Transmission in the Hemodialysis Setting: Importance of Infection Control Practices and Aseptic Technique. Poster presented at: National Kidney Foundation 2008 Spring Clinical Meeting, Dallas, Texas, April 2-6, 2008
  45. Jadoul M, Cornu C, van Ypersele de Strihou C The Universitaires Cliniques St-Luc (UCL) Collaborative Group. Universal precautions prevent hepatitis C virus transmission: A 54 month follow-up of the Belgian Multicenter Study. Kidney Int. 1998;53:1022–1025
  46. Petrosillo N, Gilli P, Serraino D, et al. Prevalence of infected patients and understaffing have a role in hepatitis C virus transmission in dialysis. Am J Kidney Dis. 2001;37:1004–1010
  47. Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial. 2005;18:52–61
  48. Jadoul M, Cornu C, van Ypersele de Strihou C The UCL Collaborative Group. Incidence and risk factors for hepatitis C seroconversion in hemodialysis: A prospective study. Kidney Int. 1993;44:1322–1326
  49. Bloom RD, Sayer G, Fa K, Constantinescu S, Abt P, Reddy KR. Outcome of hepatitis C virus-infected kidney transplant candidates who remain on the waiting list. Am J Transplant. 2005;5:139–144
  50. Knoll GA, Tankersley MR, Lee JY, Julian BA, Curtis JJ. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. Am J Kidney Dis. 1997;29:608–614
  51. Pereira BJ, Natov SN, Bouthot BA, et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease (The New England Organ Bank Hepatitis C Study Group). Kidney Int. 1998;53:1374–1381
  52. Abbott KC, Bucci JR, Matsumoto CS, et al. Hepatitis C and renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol. 2003;14:2908–2918
  53. Meier-Kriesche HU, Ojo AO, Hanson JA, Kaplan B. Hepatitis C antibody status and outcomes in renal transplant recipients. Transplantation. 2001;72:241–244
  54. Pereira BJ. Hepatitis C infection and post-transplantation liver disease. Nephrol Dial Transplant. 1995;10(suppl 1):S58–S67
  55. Bruchfeld A, Wilczek H, Elinder CG. Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation. Transplantation. 2004;78:745–750
  56. Morales JM, Dominguez-Gil B, Sanz-Guajardo D, Fernandez J, Escuin F. The influence of hepatitis B and hepatitis C virus infection in the recipient on late renal allograft failure. Nephrol Dial Transplant. 2004;19(suppl 3):Siii72–Siii76
  57. Abbott KC, Lentine KL, Bucci JR, et al. Impact of diabetes and hepatitis after kidney transplantation on patients who are affected by hepatitis C virus. J Am Soc Nephrol. 2004;15:3166–3174
  58. Bloom RD, Rao V, Weng F, Grossman RA, Cohen D, Mange KC. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol. 2002;13:1374–1380
  59. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3:178–185
  60. Morales JM, Pascual-Capdevila J, Campistol JM, et al. Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients. Transplantation. 1997;63:1634–1639
  61. Roth D, Cirocco R, Zucker K, et al. De novo membranoproliferative glomerulonephritis in hepatitis C virus-infected renal allograft recipients. Transplantation. 1995;59:1676–1682
  62. Kamar N, Toupance O, Buchler M, et al. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol. 2003;14:2092–2098
  63. Campistol JM, Esforzado N, Martinez J, et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients (Pre- and post-renal transplantation assessment). Nephrol Dial Transplant. 1999;14:2704–2709
  64. Casanovas-Taltavull T, Baliellas C, Benasco C, et al. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: Results after transplantation. Am J Gastroenterol. 2001;96:1170–1177
  65. Cruzado JM, Casanovas-Taltavull T, Torras J, Baliellas C, Gil-Vernet S, Grinyo JM. Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance. Am J Transplant. 2003;3:357–360
  66. Abbott KC, Lentine KL, Bucci JR, Agodoa LY, Peters TG, Schnitzler MA. The impact of transplantation with deceased donor hepatitis C-positive kidneys on survival in wait-listed long-term dialysis patients. Am J Transplant. 2004;4:2032–2037
  67. Natov SN, Lau JY, Ruthazer R, Schmid CH, Levey AS, Pereira BJ. Hepatitis C virus genotype does not affect patient survival among renal transplant candidates (The New England Organ Bank Hepatitis C Study Group). Kidney Int. 1999;56:700–706
  68. Kasiske BL, Vazquez MA, Harmon WE, et al. Recommendations for the outpatient surveillance of renal transplant recipients (American Society of Transplantation). J Am Soc Nephrol. 2000;11(suppl 15):S1–S86
  69. Levey AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem: Approaches and initiatives—A position statement from Kidney Disease: Improving Global Outcomes. Kidney Int. 2007;72:247–259
  70. Collins AJ KB, Herzog C, et al. Excerpts from the United States Renal Data System 2007 Annual Data Report. Am J Kidney Dis. 2008;51(suppl 1):S1–S320
  71. McHutchison JG, Poynard T, Pianko S, et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C (The International Hepatitis Interventional Therapy Group). Gastroenterology. 2000;119:1317–1323

 Reprint requests to: Donna Fingerhut, National Kidney Foundation, 30 E 33rd St, New York, NY 10016. E-mail: donnaf@kidney.org

PII: S0272-6386(08)01243-2

doi: 10.1053/j.ajkd.2008.08.005

American Journal of Kidney Diseases
Volume 52, Issue 5 , Pages 811-825 , November 2008

Article Tools